// App-Quantinova.ai

e12012 : Fulvestrant as maintenance therapy after first-line chemotherapy in postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer patients (FANCY): A prospective, multicenter, single arm phase II study.

Researchers

Presenter

  • Shusen Wang

Principal Investigators

  • Fei Xu

  • Quchang Ouyang

  • Zhongyu Yuan

  • Danmei Pang

  • Huimin Yuan

  • Roujun Peng

  • Wen Xia

  • Qiufan Zheng

Medical Centers

  • Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

  • Hunan Cancer Hospital, Changsha, China

  • Foshan No. 1 People's Hospital, Foshan, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Fulvestrant

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT02000193

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved